Copyright: ©Author(s) 2026.
World J Psychiatry. Aug 19, 2026; 16(8): 117931
Published online Aug 19, 2026. doi: 10.5498/wjp.117931
Published online Aug 19, 2026. doi: 10.5498/wjp.117931
Table 3 Clinical safety evaluation, n (%)
| Safety | Control group (n = 66) | Observation group (n = 79) | χ2 value | P value |
| Mucositis | 2 (3.03) | 2 (2.53) | 0.033 | 0.855 |
| Diarrhea | 6 (9.09) | 4 (5.06) | 0.908 | 0.341 |
| Alopecia | 8 (12.12) | 7 (8.86) | 0.412 | 0.521 |
| Anorexia | 13 (19.70) | 10 (12.66) | 1.335 | 0.248 |
| Nausea | 2 (3.03) | 4 (5.06) | 0.375 | 0.541 |
| Insomnia | 1 (1.52) | 3 (3.80) | 0.698 | 0.403 |
| Sexual dysfunction | 0 (0.00) | 0 (0.00) | - | - |
| Agitation | 0 (0.00) | 0 (0.00) | - | - |
- Citation: Zhu XX, Zhao S, Xu Q, Tang R, Xu LX, Zhou YJ, Zhang DY. Fluoxetine plus psychological intervention for chemotherapy-managed colon cancer patients: Impact on mood and influencing factors. World J Psychiatry 2026; 16(8): 117931
- URL: https://www.wjgnet.com/2220-3206/full/v16/i8/117931.htm
- DOI: https://dx.doi.org/10.5498/wjp.117931